JP2018529380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529380A5 JP2018529380A5 JP2018534523A JP2018534523A JP2018529380A5 JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5 JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3
- car
- nucleic acid
- isolated
- isolated nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021189789A JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222695P | 2015-09-23 | 2015-09-23 | |
| US62/222,695 | 2015-09-23 | ||
| PCT/US2016/053577 WO2017053889A2 (en) | 2015-09-23 | 2016-09-23 | Flt3 directed car cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189789A Division JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529380A JP2018529380A (ja) | 2018-10-11 |
| JP2018529380A5 true JP2018529380A5 (enExample) | 2019-10-31 |
| JP7054924B2 JP7054924B2 (ja) | 2022-04-15 |
Family
ID=58387435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534523A Expired - Fee Related JP7054924B2 (ja) | 2015-09-23 | 2016-09-23 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| JP2021189789A Pending JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189789A Pending JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10961312B2 (enExample) |
| EP (2) | EP3352784A4 (enExample) |
| JP (2) | JP7054924B2 (enExample) |
| KR (1) | KR20180053744A (enExample) |
| CN (1) | CN109310744A (enExample) |
| AU (2) | AU2016326721C1 (enExample) |
| CA (1) | CA2999037A1 (enExample) |
| HK (1) | HK1258921A1 (enExample) |
| WO (1) | WO2017053889A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180053744A (ko) * | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| US11299546B2 (en) | 2016-05-27 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| AU2017382883B2 (en) | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| TWI843344B (zh) * | 2017-06-02 | 2024-05-21 | 美商輝瑞大藥廠 | 對ｆｌｔ３具特異性之抗體及其用途 |
| US12296012B2 (en) * | 2017-06-02 | 2025-05-13 | Pfizer Inc. | Chimeric antigen receptors targeting FLT3 |
| EP3661511A1 (en) * | 2017-08-01 | 2020-06-10 | Julius-Maximilians-Universität Würzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| AU2018365080B2 (en) * | 2017-11-10 | 2025-07-24 | Jura Bio, Inc. | Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases |
| CN109988759A (zh) * | 2017-12-29 | 2019-07-09 | 上海细胞治疗研究院 | 一种在t细胞中具有高转录活性的嵌合启动子 |
| US20190328785A1 (en) * | 2018-04-30 | 2019-10-31 | The Board Of Regents Of The University Of Oklahoma | Flt3-binding chimeric antigen receptors, cells, and uses thereof |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
| FI3886875T3 (fi) * | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| AU2019404098A1 (en) | 2018-12-18 | 2021-05-27 | Boehringer Ingelheim Io Canada Inc. | FLT3 agonist antibodies and uses thereof |
| CA3133333A1 (en) | 2019-04-30 | 2020-04-30 | Brian Scott GARRISON | Chimeric receptors and methods of use thereof |
| KR20210033436A (ko) * | 2019-09-18 | 2021-03-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| KR102287180B1 (ko) | 2019-10-01 | 2021-08-09 | 충북대학교 산학협력단 | Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| CA3174812A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Cell |
| WO2021212069A1 (en) * | 2020-04-17 | 2021-10-21 | City Of Hope | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
| CN111647071B (zh) * | 2020-06-17 | 2023-05-05 | 深圳豪石生物科技有限公司 | 识别靶细胞表面抗原的t细胞受体及其组合物 |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| AU781396B2 (en) | 1999-07-20 | 2005-05-19 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| EP1373536B9 (en) | 2001-03-13 | 2009-09-02 | Novartis AG | Lentiviral packaging constructs |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| JP5944831B2 (ja) | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| WO2012082841A2 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| AU2013222288A1 (en) | 2012-02-22 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| NZ711807A (en) | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
| PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| EP2964753B1 (en) * | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3057994B1 (en) | 2013-10-15 | 2020-09-23 | The Scripps Research Institute | Peptidic chimeric antigen receptor t cell switches and uses thereof |
| EP3057991B8 (en) | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| EP4303229A3 (en) * | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| CN104091269A (zh) | 2014-06-30 | 2014-10-08 | 京东方科技集团股份有限公司 | 一种虚拟试衣方法及虚拟试衣系统 |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| HK1243333A1 (zh) | 2014-10-31 | 2018-07-13 | The Trustees Of The University Of Pennsylvania | 用於修饰的t细胞的方法和组合物 |
| EP3608408A1 (en) | 2014-12-15 | 2020-02-12 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US20160166613A1 (en) | 2014-12-15 | 2016-06-16 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| ES2884844T3 (es) | 2015-03-09 | 2021-12-13 | Agensys Inc | Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| US10286092B2 (en) * | 2015-08-25 | 2019-05-14 | Ucl Business Plc | Detecting a therapeutic cell |
| KR20180053744A (ko) * | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| TWI843344B (zh) | 2017-06-02 | 2024-05-21 | 美商輝瑞大藥廠 | 對ｆｌｔ３具特異性之抗體及其用途 |
| US20210301024A1 (en) | 2018-07-04 | 2021-09-30 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
-
2016
- 2016-09-23 KR KR1020187011302A patent/KR20180053744A/ko not_active Ceased
- 2016-09-23 CA CA2999037A patent/CA2999037A1/en not_active Abandoned
- 2016-09-23 AU AU2016326721A patent/AU2016326721C1/en not_active Ceased
- 2016-09-23 WO PCT/US2016/053577 patent/WO2017053889A2/en not_active Ceased
- 2016-09-23 EP EP16849810.3A patent/EP3352784A4/en not_active Withdrawn
- 2016-09-23 EP EP19170050.9A patent/EP3569244A1/en not_active Withdrawn
- 2016-09-23 CN CN201680065509.1A patent/CN109310744A/zh active Pending
- 2016-09-23 HK HK19101399.4A patent/HK1258921A1/zh unknown
- 2016-09-23 JP JP2018534523A patent/JP7054924B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-13 US US15/811,608 patent/US10961312B2/en not_active Expired - Fee Related
-
2021
- 2021-03-02 AU AU2021201329A patent/AU2021201329A1/en not_active Abandoned
- 2021-03-11 US US17/199,332 patent/US20210269534A1/en not_active Abandoned
- 2021-11-24 JP JP2021189789A patent/JP2022046461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529380A5 (enExample) | ||
| Kamiya et al. | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells | |
| JP2017537622A5 (enExample) | ||
| Barrow et al. | The natural cytotoxicity receptors in health and disease | |
| JP2016502512A5 (enExample) | ||
| RU2014118555A (ru) | Химерные антигенные рецепторы к cd22 | |
| Eagle et al. | ULBP6/RAET1L is an additional human NKG2D ligand | |
| Schildberg et al. | Coinhibitory pathways in the B7-CD28 ligand-receptor family | |
| Severson et al. | Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate β1 integrin levels, and enhance cell migration | |
| JP2014534207A5 (enExample) | ||
| Ito et al. | Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity | |
| Cosman et al. | ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor | |
| JP2022109953A5 (enExample) | ||
| JP2018505139A5 (enExample) | ||
| JP2022113880A (ja) | 免疫調節性融合タンパク質およびその使用 | |
| JP2021506243A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| HRP20220799T1 (hr) | Klaudin-18-2-specifični imunoreceptori i stanični epitopi t | |
| JP2017513478A5 (enExample) | ||
| AU2017384900A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| RU2017105515A (ru) | Сигнальная система | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2021505663A5 (enExample) | ||
| GB2541599A (en) | Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein | |
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 |